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Duchenne muscular dystrophy (DMD) is an incurable disease and the search for a cure is a challenging
journey. However, with recent encouraging progress, we are seeing a light at the end of a long tunnel.
This review focuses on several main strategies in gene therapy, including truncated dystrophin gene
transfer via viral vectors, antisense mediated exon skipping to restore the reading frame, and read-
through of translation stop codons. An exon skipping agent, eteplirsen, and a termination codon read
drug, ataluren, are currently the most promising therapies. With better understanding of the molecular
mechanism, gene therapy has improved with regard to the key areas of gene stability, safety, and route of
delivery. Consequently, it has emerged as an exciting and hopeful means for novel treatment of this
devastating disease.
Copyright  2014, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Duchenne muscular dystrophy (DMD) is a recessive X-linked
disorder caused by mutations in the dystrophin gene. It is the most
common and severe type of muscular dystrophy with an estimated
incidence of 1 in 3500 live newborn boys [1]. The dystrophin pro-
tein is vital for structural stability of muscle tissue; therefore, its
absence results in muscle degeneration. The prognosis for this
multisystemic disease is bleak, as DMD patients become dependent
and wheelchair bound by their teens. Cardiomyopathy and respi-
ratory failure usually ensue as fatal complications in the early
second and third decades of life, with amean age at death of around
19 years [2]. Although it has been described since 1880, this fatal
monogenic disorder is still incurable.
DMD patients typically begin to show symptoms of clumsiness
and difﬁculty in walking at the age of 4e5 years. The diagnosis is
suspected from the clinical picture with a serum creatinine kinase
>10 times the normal limit. Muscle biopsy shows almost completent of Internal Medicine, Fac-
ra Malaysia, 43400 Serdang,
8947 2585.
Sulaiman).
elief Tzu Chi Foundation. Publisheor total absence of the dystrophin protein [3]. The diagnosis of this
rare disease is conﬁrmed by genetic study [4].
2. Current available therapy
The current therapies for patients with DMD are based on an
attempt to improve the phenotypes of the disease. Several methods
have been tried, such as maintaining calcium homeostasis with
calcium channel blockers, decreasing inﬂammation and increasing
muscle strength using corticosteroids and beta-2 adrenergic
agonist, and increasing muscle progenitor proliferation. However,
only treatment with corticosteroids has been found to be effective
to prolong ambulation andmuscle strength [5]. Corticosteroids also
have the proven advantages of cost-effectiveness and convenience
of administration. The issues of the best choice of steroid and the
dosing regimen remain controversial [2]. Evidence from random-
ized controlled trials has suggested that the most beneﬁcial treat-
ment is with prednisolone 0.75 mg/kg/day [5]. The disadvantage of
this treatment is that it does not restore function that is already
lost, and hence, early commencement of corticosteroid treatment is
required [6]. Furthermore, the signiﬁcant long-term adverse effects
of corticosteroids are also a limiting factor, as life-long treatment is
needed in this chronic progressive disease [5].
Because the current available therapy for DMD merely provides
intermediate symptomatic beneﬁt, extensive efforts have beend by Elsevier Taiwan LLC. All rights reserved.
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underlying primary monogenic genotype defect.3. Understanding the molecular mechanism
The dystrophin gene was discovered in 1986 by a positioning
cloning technique. This gene has 79 exons and 2.6 million base
pairs, with an enormous size of 2.4 Mb [7]. So far, it is the largest
gene known in humans and consequently is at risk of sporadic
mutations, with variable phenotypes ranging from the mild Becker
muscular dystrophy (BMD) to the severe DMD [8]. These mutations
occur from various mechanisms; about 65% are due to deletion,
approximately 20% are from duplication, and the remaining 15% are
nonsense and other small mutations [9]. Deletions can occur in one
or more exons of the dystrophin gene. If the remainder of the gene
can still be spliced together into RNA that avoids a frameshift
“nonsense” codon (in-frame deletion mutation), a milder pheno-
type (BMD) is usually observed. Deletion mutations that result in
new neighboring exons (junction) that do not share the same
reading frame show a frameshift mutation, loss of dystrophin
protein, and clinically severe DMD [10].
The dystrophin protein that is encoded by the dystrophin gene is
important for the connection that links and secures the cytoskel-
eton of a muscle ﬁber to the sarcolemma with the surrounding
extracellular matrix. Dystrophin prevents muscle damage from
mechanical stress by acting like a spring, working with other
muscle proteins in the event of stretching and contraction [11].
Therefore, without its protective function, muscle ﬁbers are prone
to damage, as the process of calcium inﬂux, inﬂammation and ne-
crosis will eventually cause destruction of the muscles [12].
Dystrophin protein is located on the cytoplasmic surface of the
sarcolemma, and is integrated in a protein connection known as the
dystrophin glycoprotein complex (DGC) [13,14]. This protein com-
plex consists of other membrane-associated proteins such as
sarcoplasmic proteins, transmembrane proteins, and extracellular
proteins, which bind to one of the protein domains of dystrophin. It
provides mechanical links to the extracellular matrix that are vital
for maintaining stability of the muscle membrane [15].
Dystrophin has four major domains with different functions
[16]. The ﬁrst domain is the N-terminal, which binds to the cyto-
skeleton via F-actin (ﬁlamentous actin). Many patients who lack
this domain exhibit amoderate to severe BMD phenotype, although
the remaining protein domains are intact [10]. The second domain
is 24 spectrin-like repeats, and is a central rod domain. Most of the
deletion mutations occur in this domain, but fortunately, this ap-
pears to be the least critical for dystrophin function. Deletion and
duplication of this region result in mild Becker’s dystrophy phe-
notypes, although the mutations are extensive. The third domain is
the most important domain for dystrophin function. This cysteine-
rich domain, which binds together with beta-dystroglycan, is a
signiﬁcant component of the DGC. The phenotypes of severe DMDTable 1
Summary of the different approaches in gene therapy.
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Exon 51 skipping AO compounds
(1) PMO (i.e. eteplirsen)
(2) 20-O-MeAO (i.e. drisapersen)
(1) Gentamici
(2) Ataluren (P
AO ¼ antisense oligonucleotide; PMO ¼ phosphorodiamidate morpholino oligomer.are the consequences of lacking in this domain [10]. The fourth
domain has only has a minor role inmembrane integrity [7]. This C-
terminal domain binds to alpha-dystrobrevin and DGC [17].
This knowledge of the dystrophin gene and protein, with the
associated mutations, has provided essential understanding of the
genotype-phenotype relation. In the same dystrophin gene,
different mutations can result in different phenotypes. This concept
is very important to strategize the therapeutic approach for DMD.
4. Gene therapy and viral vector technology
4.1. Gene therapy
Several promising strategies have been described in gene ther-
apy for DMD. The main approach is to either replace or repair the
mutated dystrophin gene or transcript. The three main approaches
described here are gene transfer or replacement, antisense-
mediated exon skipping and read-through stop codon [18].
Table 1 summarizes the different approaches in gene-based
therapy.
4.2. Viral vectors
The success of gene transfer therapy depends on the efﬁciency
of the gene transfer vector. The usual vector for gene transfer
therapy in neurological disorders, including DMD, is a virus. Virus
has been chosen instead of a synthetic vector or ex vivo gene
transfer because of its capability to evolve and infect speciﬁc cell
populations. Different types of viruses have been used as gene
transfer vectors for DMD, such as herpes simplex virus, lentivirus,
adenovirus and adeno-associated virus (AAV). Adenovirus was the
early preferred delivery vehicle to muscle [19], but because of the
limited duration of gene expression in adenovirus [20], it was later
replaced by AAV. AAV is a type of parvovirus that is not associated
with human disease. This small virus has a better safety proﬁle than
adenovirus since it is less immunogenic [7]. However, a single
stranded genome of AAV demands a lytic helper virus for its pro-
duction via replication [21]. With the advances in recombinant
technology, this shortcoming has been overcome by combining
these different viruses into a new recombinant virus, known as a
recombinant AAV (rAAV). At present, this rAAV is themost common
vector used and has been proven effective in a Phase I study [22].
The rAAV has 12 known serotypes and they have been used via
different routes and targets. The most utilized serotypes for direct
gene delivery to skeletal muscle, mainly for localized treatment, are
rAAV-1 and rAAV-2. The gene also can be distributed systemically
using the serotypes rAAV-6, rAAV-8, and rAAV-9 [23]. Long-term
stable gene expression has been reported in mice, dogs, and rhe-
sus monkeys after intramuscular rAAV injection [24]. At the same
time, intravenous injection has also been proven stable for at least a
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delivery is needed. This makes the intravenous route of gene de-
livery preferable, since it is proven to effectively deliver the gene to
all skeletal muscles including the heart [24,26].
5. Gene replacement
In theory, the ideal gene transfer strategy for DMD patients is to
place a normal copy of the dystrophin gene into the targeted area
for delivery to all muscle cells. Since this is not possible yet, an
alternative strategy is to generate artiﬁcial genes that can encode a
protein as functional as normal dystrophin. This gene would be
delivered via viral vectors.
However, it is difﬁcult for the virus to accommodate the dys-
trophin gene because it is so large. Viral rAAV can only accommo-
date a small gene of 6 kb, whereas the true full-length of dystrophin
complementary DNA is 14 kb. This problem is solved with the
construction of a truncated dystrophin gene, known as mini-
dystrophin and micro-dystrophin [27].
This approach came after observation of a BMD patient whose
mutationwas a rod domain deletion (exon 17e48). The patient had
only mild disease and was still ambulant at the age of 61 years,
despite deletion of almost 50% of the coding information [28]. This
suggests that the rod domain has limited function in muscle sta-
bility. The mini-dystrophin (5 or more) and micro-dystrophin (4)
spectrin repeats with deletion of the C-terminal and removal of the
50 and 30 untranslatable repeat emerged after this observation.
These promising mini-genes have been tested successfully in ani-
mal models [29]. A study by Harper et al (2002) [30] showed that
multiple modiﬁcations in dystrophin improvemuscle ability inmdx
mice. The best example is the RH2-R19 construct, where a spectrin-
like repeat was restored in a smaller rod domain. It resulted in fully
functioning mini-genes that can be transferred using viral vectors
[30].
Currently, this gene therapy using mini-genes has progressed
into early clinical research. Two pioneering clinical trials for gene
transfer strategy were published in 2012. In a Phase I/IIa trial done
collaboratively between some universities and hospitals in the
United States, micro-dystrophin was successfully delivered via a
modiﬁed AAV vector to the biceps muscle of six DMD patients [22].
In the other study in patients with limb girdle muscular dystrophy
type 2C in France, utilization of AAV serotype 1 gene transfer was
also found effective for the induction of g-sarcoglycan protein
expression without major side effects [31].
Besides this promising mini genes technology, other methods of
efﬁcient large gene delivery is also being investigated. Another
novel approach was recently discovered, whereby the large gene is
split into a few vectors. Known as the trans-splicing strategy, it was
successfully proven to deliver the full-length DMD coding sequence
to themusculature in dystrophicmdxmice using a triple AAV trans-
splicing vector [32]. This success also provides for future treatment
of other inherited diseases in addition to DMD via large therapeutic
gene delivery.
Patient safety is still the key concern in gene replacement
strategies. Both gene and viral vector delivered to muscles may
cause a harmful immune response in patients. Since some patients
may have little native dystrophin in their muscle, the new dystro-
phin can cause a cellular immune response resulting in production
of destructive cytotoxic T cells [24]. In addition, the presence of
foreign vector capsid proteins may provoke the humoral immune
response [18]. However, delivery of micro-dystrophin with a more
native micro-utrophin was found to reduce the risk of cellular
immunogenicity [24]. Utrophin protein has a structure and function
identical to dystrophin and it is commonly found in muscle during
fetal development [33]. Its upregulation in patients with DMD [34]has led to the belief that utrophin can be used to compensate
dystrophin function in DMD [35]. Another less immunogenic
technique uses striated muscle-speciﬁc promoters, such as a
modiﬁed creatinine kinase promoter. It appears to have high level
of expression selectivity in the desired muscle tissues [36].
Although research on gene transfer has been intense for the past
two decades since the discovery of the dystrophy gene, a few
problems have hindered progress. These include the huge dystro-
phy gene, possible harmful immunological reactions, and the dif-
ﬁculty in ﬁnding an ideal vector with an effective delivery system
[24]. Having identiﬁed the major obstacles in gene therapy, stra-
tegies should now focus on the search for another vehicle that can
accommodate the large length of dystrophin with widespread tis-
sue delivery and most importantly, has non-immunogenic
properties.
6. Antisense-mediated exon skipping
This approach aims to repair the gene product by using an exon-
skipping construct method. To date, this strategy is the most
advanced in clinical trials. The dystrophin gene is the right target,
since almost two-thirds of DMD patients have out-of-frame de-
letions or duplications [37]. When the open reading frame is dis-
rupted, no functional dystrophin protein is produced and this leads
to severe disease.
By contrast, in BMD, which is caused by the same gene, the
reading frame is not disrupted as in DMD. Therefore, BMD patients
still have the ability to produce at least some functional dystrophin,
contributing to less severe disease. There is a variability of pheno-
types in BMD as well, with some patients having near normal
muscle. The majority of patients with BMD have a normal life ex-
pectancy and they are able to maintain ambulation into late middle
age [38,39]. Based on this milder BMD concept, an antisense
oligonucleotide (AO) or splice-switching oligomer approach for
DMD is applied to restore the disordered reading frame. The
intended outcome is a conversion of the debilitating disorder of
DMD to less severe disease, like BMD.
AO was ﬁrst discovered in 1978 [40], and later modiﬁed in the
early 1990s. At present, it has emerged as a new class of therapeutic
agents for various diseases. For DMD, AO is used to redirect and
modulate pre-mRNA splicing, thus inducing mRNA stabilization to
restore the dystrophin protein function [38]. Although the protein
produced is truncated, the key functional domains are retained.
The two AOs that have demonstrated promising results in ani-
mal models for DMD are phosphorodiamidate morpholino oligo-
mers (PMO) and 20-O-methyl phosphorothioate backbone (20-O-
MeAO). PMO has a morpholino ring-based neutrally charged
backbone with enhanced serum stability and high resistance to
nuclease degradation. It is capable of producing dystrophin ranging
from 5% to 20%, depending onwhichmuscle ﬁbers have been tested
[38]. For example, the level of protein expression in cardiac muscle
is extremely low. As DMD patients usually succumb to cardiomy-
opathy, this discouraging ﬁnding has led researchers to search for
better modiﬁcation strategies. Currently, cell-penetrating peptides
(CPPs), which are short cationic peptides that enhance cell uptake,
are combined with AO. This combination is likely to be more
effective as splice-correcting agents compared with AO alone.
Recent study on arginine-rich CPPs conjugated to a PMO known as
Pip5e-PMO showed potential in enhancing delivery to the heart
[41].
Meanwhile, a study showed that 20-O-Me AO produced higher
dystrophin protein levels in mdx dystrophin mice compared with
wild-type mice, indicating that uptake in degenerated muscle ﬁ-
bers is higher than in normal ﬁbers [42]. Although a few other
animal studies have yielded promising results [43], 20-O-MeAO is
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on bothmdxmice and a more complex mammal, a DMD dog. It was
found that PMO was better in terms of safety proﬁle, wide thera-
peutic range, and ability to produce high levels of dystrophin [44].
This ﬁndingwas reﬂected by a recently completed Phase III trial of a
20-O-MeAO AO drug developed collaboratively by Prosensa and
GlaxoSmithKline, called drisapersen [45]. The pharmaceutical
companies had announced a preliminary report that the exon
skipping approach drug did not meet the primary endpoint.
However, it is still under full analysis and the formal results of the
study will be published in mid-2014 [46].
Eteplirsen, a PMO drug which is another AO, looks more
promising than drisapersen. Eteplirsen was developed by Sarepta
Therapeutics (previously known as AVI Biopharma), targeting to
skip exon 51 of the dystrophin gene. It demonstrated a favorable
clinical outcomewith a good safety proﬁle in 19 DMD patients after
the completion of a Phase Ib/II clinical trial [47,48]. In the latest
randomized control trial published, eteplirsen continues to show
its potential to induce dystrophin production. Although this was a
small study of 12 boys with DMD, the double-blind, placebo-
controlled trial found that high dose eteplirsen signiﬁcantly
restored dystrophin with improvement in ambulation without
major adverse events [49].
The excision of exon 51 should be beneﬁcial to approximately
13% of all DMD patients and by only 12 mono-skipping events,
about 75% of the mutations in DMD patients may be converted to a
condition similar to the milder BMD [47]. However, in a third of all
DMDmutations, skipping of more than a single exon is necessary. A
study by Forrest and colleagues in 2010 [47] showed that removal
of two or more exons was possible and they managed to remove
exons 17 and 18 with variable success. With further improvements,
this approach may rapidly progress to a clinical trial.
Despite its huge potential, AO shortcomings have surfacedwhen
dystrophin restoration was less than half of normal. Furthermore,
this strategy is unsuitable with patients who have mutations in the
promoter region, deletion of the ﬁrst or last (79th) exon, large de-
letions of more than 35 exons and deletion of the domain bound by
dystroglycan (exons 62e69). Fortunately, all of these are rare. Most
of the deletions are typically located between 43 and 55, and these
mutations have been shown to be reparable in animal study. A
clinical trial with DMD patients is ongoing [23].
7. Read-through of stop-codons
Another strategy to correct mutated dystrophin pre-mRNa other
than AO, is by giving drugs to induce ribosomal read-through of
premature stop codons, hence suppressing the nonsensemutations
[48]. This approach can be used in almost 15% of DMD patients who
have substitution mutations [49]. During protein translation, an
aminoglycoside was discovered to inﬂuence cells to ignore both
regular and aberrant stop codons, allowing the production of
functional protein [50]. Studies on gentamicin, an aminoglycoside
antibiotic, showed beneﬁcial effects in the restoration of functional
dystrophin protein [50,51]. For example, a regimen of gentamicin
7.5 mg/kg body weight administered every week or biweekly for
6 months increased the dystrophin level up to 13e15%, with a
signiﬁcant reduction of the serum creatinine kinase level as well
[52]. Concerns regarding vestibular and renal toxicity, adverse
events secondary to aminoglycosides, can be addressed with
proper prescreening and Cystatin-C measurement [52]. Addition-
ally, the risk of toxicity was found to be lower with delivery of
gentamicin via hybrid liposomes [53]. In spite of the few positive
trials of gentamicin, a short 2-week trial failed to show any beneﬁt,
even in a high-dose gentamicin group [51]. Because of this
ambiguous result, coupled with the notorious toxicities andshortcomings of intravenous administration of aminoglycosides,
other alternatives have been explored. As a result, ataluren, a new,
safer, oral drug was discovered. Previously known as PTC124, it has
been shown to restore dystrophin production up to 20e25% inmdx
mice within 2e8 weeks after drug introduction [54].
This oral small molecule compound drug has completed Phase I
and IIa studies. It has demonstrated an ability to increase the
expression of dystrophin protein and reduce creatinine kinase at
lower and moderate treatment dose levels with no severe adverse
events [55]. A Phase II, multicenter, double-blinded, randomized
control trial found that at 48 weeks, ambulatory DMD patients
treated with low dose ataluren had a slower decline in the 6-
minute walk distance and no serious adverse events were
observed [56]. However, there was no improvement noted in the 6-
minute walk distance in the high-dose ataluren group, with results
similar to those in the placebo group. A Phase III study of ataluren
by PTC Therapeutics (USA) is currently underway and is estimated
to be completed by mid-2015 [57].
8. Future therapy
With the advancement of medical technology and gene therapy,
new strategies will come about. One example is combinations of
adult stem cells and gene transfer developed by Kazuki and col-
leagues [58]. They utilized a fully stable length of dystrophin gene
and transferred the gene using a human artiﬁcial chromosome [58].
The therapy managed to correct a large deletion in a DMD patient
involving exons 4e43. Induced pluripotent stem (iPS) cells were
developed using the patient’s own ﬁbroblasts. As a result, corrected
iPS cells were generated, and in vivo normal muscle cells were
produced. The corrected iPS cells need to be applied back to the
patient for the next step. The advantage of this combination stem
cell technology is the avoidance of a detrimental immune response.
Thismethod of full length dystrophin gene transfer looks promising
as a potential future therapy [58,59].
9. Conclusion
Clear understanding of the molecular mechanism has provided
exciting new opportunities for DMD gene therapy, a concept that
has gone from mere theory to clinical trials. With the current
intriguing rapid progress in gene therapy, speciﬁcally strategies for
gene transfer, antisense-mediated exon skipping, and read-through
of stop-codons, the possibility of a cure for DMD is more promising.
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